Novo Nordisk beating earnings, raising guidance

NVO movement today: "Novo also announced that, pending regulatory approvals, the Wegovy pill will launch outside the U.S. during the second half of 2026." Furthermore: "Novo’s results come as investor sentiment around the company had slowly begun to recover following the launch of the Wegovy pill in the U.S. in early January, which analysts hailed as 'one of the best launches ever.'" Source: [https://www.cnbc.com/2026/05/06/wegovy-glp1-weight-loss-novo-nordisk-earnings-stock-nvo-ozempic.html](https://www.cnbc.com/2026/05/06/wegovy-glp1-weight-loss-novo-nordisk-earnings-stock-nvo-ozempic.html)